CD73 targeted antisense oligonucleotide therapeutic - Secarna Pharmaceuticals
Alternative Names: CD73 antisense oligonucleotide - Secarna PharmaceuticalsLatest Information Update: 07 Sep 2023
At a glance
- Originator Secarna Pharmaceuticals
- Class Antineoplastics; Antisense oligonucleotides
- Mechanism of Action 5-nucleotidase inhibitors; Gene silencing
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
- Available For Licensing Yes
Highest Development Phases
- Preclinical Cancer
Most Recent Events
- 24 Jul 2023 CD73 targeted antisense oligonucleotide therapeutic - Secarna Pharmaceuticals is available for licensing as of 24 Jul 2023. https://www.secarna.com/partnering
- 24 Jul 2023 Preclinical trials in Cancer in Germany (unspecified route) (Secarna Pharmaceuticals Pipeline, July 2023)